"PlantForm is ideally positioned to meet the fast-growing demand for affordable antibody medicines: it has a novel, versatile and scalable manufacturing platform with an excellent management team that can execute on a well thought out plan."
President & CEO, Dalton Chemical
Abbott Acquires Facet Biotech
The deal — worth a total of $450 million — gives Abbott access to biologics in two key therapeutic areas: immunology and oncology. Ensemble Discovery partners with Pfizer
Strategic alliance aims to discover and develop novel drugs against high-value pharmaceutical targets. Pfizer-Protalix Deal Bolsters Competition for Genzyme
Pfizer has agreed to pay at least $60 million for rights to Protalix BioTherapeutics’s experimental drug for Gaucher’s disease.
An independent expert panel of Canadian and U.S. venture capitalists selected PlantForm as a leading investment opportunity and winner in the life sciences category of Canada’s Top 10™ Competition
Don Stewart, PhD
President & CEO Ron Hosking, CA
Chief Financial Officer Chris Hall, PhD
Chief Scientific Officer
Board of Directors
Mark Goldberg, PhD (Chair)
Founder & Director R&D
GlobalTox, a division of MTE Consultants Inc.
CEO, Viron Therapeutics Warren Whitehead
former CFO, Arius Research Chris Hall, PhD
CSO, PlantForm Corp. Don Stewart, PhD
President & CEO, PlantForm Corp.